Morphinan Derivatives for Selective Opioid K Receptor Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid κ receptor agonists suffer from sedative and aversive effects, limiting their clinical use as analgesics, and there is a lack of κ receptor-selective agonists with potent analgesic activity without these adverse effects.
Innovation Solution
Development of specific morphinan derivatives with high selectivity for the opioid κ receptor, represented by the formula (I), which are synthesized through a multi-step process involving reactions with 2-chloroacrylonitrile, hydrogenation, trifluoromethanesulfonation, and other chemical transformations to produce compounds with potent agonist activity and reduced sedative and aversive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If κ receptor agonists are used to achieve analgesic effect, then analgesic activity is improved, but sedative effect and drug aversive effect occur
Solution Approach 1:
The invention modifies the chemical structure of morphinan derivatives by changing parameters such as substituting hydroxyl groups with methoxy groups, adding alkyl groups at specific positions, and modifying the nitrogen substituent patterns. These structural parameter changes result in compounds with enhanced κ receptor selectivity and agonist activity while reducing sedative and aversive effects, as demonstrated by compounds of formula (I) showing potent analgesic activity without the adverse effects of conventional κ agonists like nalfurafine
2Reliability
If morphine with strong μ receptor affinity is used, then strong analgesic effect is achieved, but adverse events such as drug dependence, respiratory depression and constipation occur
Solution Approach 1:
The invention extracts and isolates the analgesic function from the harmful side effects by selectively targeting the κ receptor subtype. By designing morphinan derivatives with high κ receptor selectivity and affinity, the patent separates the desired analgesic effect from the adverse events associated with μ receptor activation, such as respiratory depression and constipation, which are specifically linked to μ receptor agonism
Solution Approach 2:
The invention applies local quality by targeting a specific receptor subtype (κ receptor) rather than acting on multiple opioid receptor types. The morphinan derivatives of formula (I) are designed to selectively bind to and activate κ receptors, providing localized therapeutic action at the receptor level, which delivers analgesia without the systemic adverse effects caused by non-selective opioid receptor activation
3Reliability
If nalfurafine is used to achieve potent analgesic activity, then κ receptor agonist effect is improved, but sedative effect is shown at analgesic dose
Solution Approach 1:
The invention systematically modifies the chemical parameters of nalfurafine and related compounds to optimize the balance between analgesic activity and sedative effects. By changing substituent patterns, molecular weight, and structural features of the morphinan core, the patent develops compounds with enhanced κ receptor selectivity that maintain potent analgesia while minimizing sedation, as evidenced by the superior profile of formula (I) compounds compared to nalfurafine
Data Source
AI summary
A morphinan derivative represented by the following formula (I), a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a medicament, an analgesic and an antipruritic drug including the same as an active ingredient:wherein R is selected from hydrogen and C1-6 alkyl, and n represents an integer of 0 to 2.